Total trials
727
Active
128
Phase 3
60
Total enrollment
2,107,637
Pipeline matrix
Showing 40 of 44 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Celestone + placebo | — | — | — | — | — | 1 | |
| Celestone + Celestone | — | — | — | — | — | 1 | |
| Inhaled corticosteroid | — | — | — | — | — | 1 | |
| Oral Corticosteroid | — | — | — | — | — | 1 | |
| Bavarian Nordic smallpox vaccine | — | — | — | — | — | 1 | |
| Typhoid VI Polysaccharide Vaccine Injectable Solution | — | — | — | — | — | 1 | |
| Semaglutide Pen Injector | — | — | — | — | — | 1 | |
| Morphine Sulphate | — | — | — | — | — | 1 | |
| Morphine Sulphate + Cough Control Therapy | — | — | — | — | — | 1 | |
| Pregabalin + Cough Control Therapy | — | — | — | — | — | 1 | |
| Faricimab | — | — | — | — | — | 1 | |
| Pregabalin | — | — | — | — | 3 | ||
| ketamine hydrochloride | — | — | — | — | — | 1 | |
| rivaroxaban and ASA | — | — | — | — | — | 1 | |
| Low-molecular weight heparin | — | — | — | — | — | 1 | |
| Fondaparinux | — | — | — | — | — | 1 | |
| Direct Oral Anticoagulant | — | — | — | — | — | 1 | |
| Upadacitinib Oral Product | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Vancomycin | — | — | — | — | 2 | ||
| Anti-Thymocyte Globulin | — | — | — | — | 2 | ||
| ChAd-triCoV/Mac | — | — | — | — | 2 | ||
| Psilocybin combined with Psychotherapy | — | — | — | — | — | 1 | |
| Tofacitinib 10 MG [Xeljanz] | — | — | — | — | — | 1 | |
| Bupivacaine-epinephrine | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Intravenous DNase I | — | — | — | — | — | 1 | |
| Mitomycin C | — | — | — | — | — | 1 | |
| Adenosine 5'-triphosphate | — | — | — | — | — | 1 | |
| Tetrahydrocannabinol-Cannabidiol Combination | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| Ketorolac | — | — | — | — | — | 1 | |
| Sputum-guided management and comprehensive care management | — | — | — | — | — | 1 | |
| L-Tryptophan | — | — | — | — | — | 1 | |
| Freedom SimpleCap Powder | — | — | — | — | — | 1 | |
| Withholding Levodopa | — | — | — | — | — | 1 | |
| Nutrition and Medication review | — | — | — | — | — | 1 | |
| Statin | — | — | — | — | — | 1 | |
| ACE inhibitor | — | — | — | — | — | 1 | |
| Dual antiplatelet therapy | — | — | — | — | — | 1 |
4 more active programs hidden
Next readouts
- 2023-12
- 2024-02-16
- 2024-05-18
- 2025-01-31
- 2025-03
- 2025-04-01
- 2025-09
- 2025-09
- 2025-12-31
- 2026-03
Top conditions
- Aging16
- Obesity15
- Asthma15
- Postpartum Depression14
- Stroke13
- Venous Thromboembolism11
- Cardiovascular Diseases9
- Breast Cancer9
Frequently asked questions about McMaster University
- How many clinical trials does McMaster University have on ClinicalTrials.gov?
- McMaster University is listed as the lead sponsor on 727 clinical trials in ClinicalTrials.gov, 128 of which are currently active (recruiting, enrolling, or ongoing).
- How many of McMaster University's trials are in Phase 3?
- 60 of McMaster University's trials are in Phase 3, spread across 44 active drug programs.
- What therapeutic areas does McMaster University focus on?
- McMaster University's most-studied conditions on ClinicalTrials.gov are Aging, Obesity, Asthma, Postpartum Depression, Stroke.
- When are McMaster University's next clinical trial readouts?
- McMaster University has 10 upcoming primary-completion readouts tracked here; the soonest is “Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management”, expected around 2023-12.